ProLynx
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5858 Horton St Ste 575, Emeryville, Cali...Phone Number
(341) 946-5821Website
www.prolynxinc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About ProLynx
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The companys proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.Explore more
ProLynx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProLynx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ProLynx has recently received funding, and reach out quickly before it becomes old news!
ProLynx, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ProLynx launches new products
Click to see if ProLynx had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at ProLynx
Earning: See what the market has to say on ProLynx recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ProLynx has new funding data
Check out if ProLynx is spiking on competitors!
Recommended Actions
Find VP level buyers at ProLynx
Find 2 more new buyers
Compare Similar Companies to ProLynx
Compare insights from companies similar to ProLynx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ProLynx
<$5M
1-10
Private
$70.4M
2009
AS
Alexander SteinerChief Business Officer Operations Head of Research & Development
Company Profile Activity
Activity Insights
ProLynx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ProLynx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ProLynx.
ProLynx financials insights
Gather financial insights about ProLynx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Debt
$207K
2025
Series A
$70M
ProLynx Tech Stack
A closer look at the technologies used by ProLynx
Most Recent Scoops
Person-Based
Product Development, Medical Research, Pharmaceuticals
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
ProLynx News & Media
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific OfficerCEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression - BioCentury
Chris Boulton, a former executive of Amgen Inc. (NASDAQ:AMGN), Sanofi (Euronext:SAN; NASDAQ:SNY) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN), will become CEO...Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive OfficerProLynx Announces Publication of Its Once Monthly Semaglutide in the Proceedings of the National Academy of Sciences
Single injection of ProLynx long-acting semaglutide produced 20% weight loss in diet-induced obese mice, which is comparable to multiple semaglutide injections over the same period SAN FRANCISCO, Dec. 2, 2024 /PRNewswire/ -- ProLynx Inc., a biotechnology company developing proprietary...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ProLynx
Sign Up For FreeTo access detailed company insights
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The companys proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.... Read More
